A randomized phase 2 trial to evaluate the antitumor activity of enzalutamide (EZ) and talazoparib (TALA) for the treatment of metastatic hormone-naive prostate cancer (mHNPC): ZZFIRST.

被引：1
|
作者：
Mateo, Joaquin
Borque, Angel
Castellano, Daniel E.
Castro, Elena
Climent Duran, Miguel Angel A.
Font, Albert
Lorente, David
Mellado, Begona
Rodriguez-Vida, Alejo
Cuadras, Merce
Planas, Jacques
Casanova Salas, Irene
Cordoba, Sarai
Gonzalez, Lucila
Martinez de Falcon, Marta
Fernandez, Melissa
Sampayo-Cordero, Miguel
Malfettone, Andrea
Perez-Lopez, Raquel
Carles, Joan
机构：
[1] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[2] Hosp Univ Miguel Servet, Zaragoza, Spain
[3] Hosp Univ 12 Octubre, Madrid, Spain
[4] Hosp Virgen Victoria & Reg Malaga, Inst Invest Biomed Malaga, Malaga, Spain
[5] Inst Valenciano Oncol IVO, Valencia, Spain
[6] Inst Catala Oncol, Badalona, Spain
[7] Hosp Prov Castellon, Med Oncol Dept, Castellon De La Plana, Spain
[8] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
[9] Hosp Mar, Res Inst, Med Oncol Dept, Barcelona, Spain
[10] Vall dHebron Inst Oncol, Barcelona, Spain
[11] Vall dHebron Univ Hosp, Barcelona, Spain
[12] Vall dHebron Univ Hosp, Urol Dept, Barcelona, Spain
[13] Med Sci Innovat Res MEDSIR, Barcelona, Spain
[14] Vall dHebron Inst Oncol VHIO, Radiom Grp, Barcelona, Spain
[15] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.TPS209
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS209
引用
收藏
页数：3
相关论文
共 50 条
  • [1] UpFrontPSMA: A randomized phase II study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel in metastatic hormone-naive prostate cancer (mHNPC).
    Azad, Arun
    Dhiantravan, Nattakorn
    Emmett, Louise
    Joshua, Anthony M.
    Vela, Ian
    Pattison, David A.
    Francis, Roslyn J.
    Williams, Scott
    Sandhu, Shahneen Kaur
    Davis, Ian D.
    Neha, Nitika
    Bressel, Mathias
    Murphy, Declan G.
    Hofman, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [2] Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer
    Lilleby, Wolfgang
    Gaudernack, Gustav
    Brunsvig, Paal F.
    Vlatkovic, Ljiljana
    Schulz, Melanie
    Mills, Kate
    Hole, Knut Hakon
    Inderberg, Else Marit
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (07) : 891 - 901
  • [3] Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer
    Wolfgang Lilleby
    Gustav Gaudernack
    Paal F. Brunsvig
    Ljiljana Vlatkovic
    Melanie Schulz
    Kate Mills
    Knut Håkon Hole
    Else Marit Inderberg
    Cancer Immunology, Immunotherapy, 2017, 66 : 891 - 901
  • [4] TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC).
    Agarwal, Neeraj
    Azad, Arun
    Shore, Neal D.
    Carles, Joan
    Fay, Andre P.
    Dunshee, Curtis
    Karsh, Lawrence Ivan
    Paccagnella, Maria Luisa
    Di Santo, Nicola
    Elmeliegy, Mohamed
    Lin, Xun
    Niyazov, Alexander
    Czibere, Akos
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study
    Tombal, Bertrand
    Borre, Michael
    Rathenborg, Per
    Werbrouck, Patrick
    Van Poppel, Hendrik
    Heidenreich, Axel
    Iversen, Peter
    Braeckman, Johan
    Heracek, Jiri
    Baskin-Bey, Edwina
    Ouatas, Taoufi K.
    Perabo, Frank
    De Phung
    Hirmand, Mohammad
    Smith, Matthew R.
    LANCET ONCOLOGY, 2014, 15 (06): : 592 - 600
  • [6] Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial
    Calcagno, Fabien
    Mouillet, Guillaume
    Adotevi, Olivier
    Maurina, Tristan
    Nguyen, Thierry
    Montcuquet, Philippe
    Curtit, E.
    Kleinclauss, F.
    Pivot, Xavier
    Borg, Christophe
    Thiery-Vuillemin, Antoine
    MEDICAL ONCOLOGY, 2016, 33 (08)
  • [7] Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial
    Fabien Calcagno
    Guillaume Mouillet
    Olivier Adotevi
    Tristan Maurina
    Thierry Nguyen
    Philippe Montcuquet
    E. Curtit
    F. Kleinclauss
    Xavier Pivot
    Christophe Borg
    Antoine Thiery-Vuillemin
    Medical Oncology, 2016, 33
  • [8] UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naive prostate cancer (clinical trial protocol)
    Dhiantravan, Nattakorn
    Emmett, Louise
    Joshua, Anthony M.
    Pattison, David A.
    Francis, Roslyn J.
    Williams, Scott
    Sandhu, Shahneen
    Davis, Ian D.
    Vela, Ian
    Neha, Nitika
    Bressel, Mathias
    Murphy, Declan G.
    Hofman, Michael S.
    Azad, Arun A.
    BJU INTERNATIONAL, 2021, 128 (03) : 331 - 342
  • [9] Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) vs. EZ alone in metastatic castration refractory prostate cancer (mCRPC)
    Maughan, B. L.
    Hahn, A.
    Hoffman, J.
    Morton, K.
    Gupta, S.
    Batten, J.
    Thorley, J.
    Hawks, J.
    Nachaegari, G.
    Nussenzveig, R.
    Boucher, K.
    Agarwal, N.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study
    Azad, Arun
    Fizazi, Karim
    Matsubara, Nobuaki
    Saad, Fred
    De Giorgi, Ugo
    Joung, Jae Young
    Fong, Peter C. C.
    Jones, Robert J.
    Zschaebitz, Stefanie
    Oldenburg, Jan
    Shore, Neal D.
    Dunshee, Curtis
    Carles, Joan
    Fay, Andre P.
    Lin, Xun
    DeAnnuntis, Liza L.
    Di Santo, Nicola
    Engelsberg, Arne
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345